Abstract:The newly synthesized quinoline-benzimidazole hybrids containing two types of triazole-methyl-phenoxy linkers were characterized via NMR and elemental analysis. Additional derivatization was achieved by introducing bromine at the C-2 position of the phenoxy core. These novel hybrids were tested for their effects on the growth of the non-tumor cell line MRC-5 (human fetal lung fibroblasts), leukemia and lymphoma cell lines: Hut78, THP-1 and HL-60, and carcinoma cell lines: HeLa and CaCo-2. The results obtained, presented as the concentration that achieves 50% inhibition of cell growth (IC50 value), show that the compounds tested affect tumor cell growth differently depending on the cell line and the dose applied (IC50 ranged from 0.2 to >100 µM). The quinoline-benzimidazole hybrids tested, including 7-chloro-4-(4-{[4-(5-methoxy-1H-1,3-benzo[d]imidazol-2-yl)phenoxy]methyl}-1H-1,2,3-triazol-1-yl)quinoline 9c, 2-(3-bromo-4-{[1-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methoxy}phenyl)-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 10e, 2-{4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 14e and 2-{3-bromo-4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 15e, arrested the cell cycle of lymphoma (HuT78) cells. The calculated ADMET properties showed that the synthesized compounds violated at most two of Lipinski's rules, making them potential drug candidates, but mainly for parenteral use due to low gastrointestinal absorption. The quinoline-benzimidazole hybrid 14e, which was shown to be a potent and selective inhibitor of lymphoma cell line growth, obtained the highest binding energy (-140.44 kcal/mol), by docking to the TAO2 kinase domain (PDB: 2GCD).

Synthesis of Novel Ral Inhibitors: an in Vitro and in Vivo Study

Design and Efficient Synthesis of RalA Inhibitors Containing the Dihydro‐α‐carboline Scaffold

Synthesis, structure characterization and preliminary biological evaluation of novel 5-alkyl-2-ferrocenyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives

Design, Synthesis, and Biological Evaluation of Pyrano[2,3-c]-pyrazole–Based RalA Inhibitors Against Hepatocellular Carcinoma

Synthesis and anticancer activity of novel quinazolinone-based rhodanines

Synthesis and Biological Evaluation of Novel 2-Arylamino-3-(arylsulfonyl)quinoxalines As PI3Kα Inhibitors

Novel 5-Methyl-2-[(un)substituted Phenyl]-4-{4,5-Dihydro-3-[(Un)Substituted Phenyl]-5-(1,2,3,4-Tetrahydroisoquinoline-2-Yl)Pyrazol-1-Yl}-Oxazole Derivatives: Synthesis and Anticancer Activity

Novel secondary pyridinyl amides: Synthesis, in vitro antiproliferative screenings, and molecular docking studies

Synthesis, characterization, anti-lung cancer activity, and in-silico studies of some novel triazole-based analogues as Pellizzari products

Novel 1,2,3-Triazole-Containing Quinoline-Benzimidazole Hybrids: Synthesis, Antiproliferative Activity, In Silico ADME Predictions, and Docking

Novel 5-Methyl-2,4-disubstitued-oxazole Derivatives: Synthesis and Anticancer Activity

Synthesis, Docking, and Machine Learning Studies of Some Novel Quinolinesulfonamides-Triazole Hybrids with Anticancer Activity

New 5,6,7,8‐Tetrahydro‐isoquinolines Bearing 2‐Nitrophenyl Group Targeting RET Enzyme: Synthesis, Anticancer Activity, Apoptotic Induction and Cell Cycle Arrest

Synthesis And Evaluation Of Novel 2,4-Diaminopyrimidines Bearing A Sulfoxide Moiety As Anaplastic Lymphoma Kinase (Alk) Inhibition Agents

Synthesis and biological assessment of indole derivatives containing penta-heterocycles scaffold as novel anticancer agents towards A549 and K562 cells

Synthesis and Evaluation of In-vitro Anticancer Activity of Novel Pyrimidine Derivatives

Synthesis and cytotoxicity studies of novel N-arylbenzo[h]quinazolin-2-amines

New Quinazolinone‐Thiouracil Derivatives: Design, Synthesis, Anticancer Evaluation, and In Silico Analysis

Synthesis of quinoxalines and assessment of their inhibitory effects against human non-small-cell lung cancer cells

Synthesis and Anti-Tumor Efficacy of Novel 2, 4-Diarylaminopyrimidine Derivatives Bearing N-(3-pyridinylmethyl) Urea Moiety As Anaplastic Lymphoma Kinase Inhibitors.

Synthesis, Characterization, and in Vitro Anticancer Evaluation of 2-Aryl-4-Arylsulfonyl-5-RS-1,3-Oxazoles